article thumbnail

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

The Pharma Data

Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Bayer’s Xofigo (radium-223 dichloride) is the first and only approved TAT.

article thumbnail

Unveiling Potential: Exploring Alpha Emitter Radiopharmaceuticals

XTalks

When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death. Advantages of Alpha Emitter Therapy Over the past two decades, the radiological and chemical properties of alpha emitting isotopes have regained prominence in medical physics.

DNA 66
article thumbnail

COVID-19 Pandemic Coverage

XTalks

Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like. Addressing the Rapidly Evolving Vaccine Development Landscape. Drugs and Vaccines.